Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067559 | 0.88 | MAPT (0.43) | MAPTKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL2251926 | 0.86 | MAPT (0.48) | MAPTKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL22653939 | 0.81 | — | — | |
| SCHEMBL2324102 | 0.81 | DPP7 (0.47) | MAPTKMT2AMEN1SMN1; SMN2ALDH1A1 | |
| SCHEMBL17966452 | 0.78 | HTR1A (0.53) | MAPTKMT2ASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL291961 | 0.75 | — | — | |
| SCHEMBL2302995 | 0.74 | DPP7 (0.41) | SMN1; SMN2ALDH1A1TSHRNPSR1PKM | |
| SCHEMBL1569788 | 0.74 | KDM4E (0.42) | KMT2AMEN1ALDH1A1 | |
| SCHEMBL282864 | 0.73 | — | — | |
| SCHEMBL2248603 | 0.72 | DPP7 (0.40) | DPP4DPP7DPP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10745388-B2 | Indazole compounds and uses thereof | INCYTE CORPORATION (US) | 2020-08-18 | — | — | US | claimed |
| US-20190256500-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-08-22 | — | — | US | claimed |
| US-20220356173-A1 | POLYMORPHIC FORMS OF KINASE INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF | EQUINOX SCIENCES, LLC | 2022-11-10 | — | — | US | disclosed |
| US-11053224-B2 | Polymorphic forms of kinase inhibitor compound, pharmaceutical composition containing same, preparation method therefor and use thereof | EQUINOX SCIENCES, LLC (US) | 2021-07-06 | — | — | US | disclosed |
| CN-108884080-B | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing polymorphic form, and preparation method and application of polymorphic form | 贝达药业股份有限公司 | 2020-10-27 | — | — | CN | disclosed |
| US-10745388-B2 | Indazole compounds and uses thereof | INCYTE CORPORATION (US) | 2020-08-18 | — | — | US | disclosed |
| US-20190256500-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2019-08-22 | — | — | US | disclosed |
| US-20190233403-A1 | POLYMORPHIC FORMS OF KINASE INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF | EQUINOX SCIENCES, LLC | 2019-08-01 | — | — | US | disclosed |
| EP-3502105-A1 | POLYMORPHIC FORM OF KINASE INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Betta Pharmaceuticals Co., Ltd. (CN) | 2019-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10745388-B2 | Indazole compounds and uses thereof | PDXK, PPIP5K2, PCK1 | MAPT 3880/4885KMT2A 3912/4885MEN1 2885/4885 |
| US-20190233403-A1 | POLYMORPHIC FORMS OF KINASE INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, MAP3K11 | MAPT 2508/4885KMT2A 2430/4885MEN1 1247/4885 |
| US-20220356173-A1 | POLYMORPHIC FORMS OF KINASE INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, MAP3K11 | MAPT 2508/4885KMT2A 2430/4885MEN1 1247/4885 |
| US-11053224-B2 | Polymorphic forms of kinase inhibitor compound, pharmaceutical composition containing same, preparation method therefor and use thereof | WEE2, WEE1, MAP3K11 | MAPT 2508/4885KMT2A 2430/4885MEN1 1247/4885 |
| US-20190256500-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | PDXK, PPIP5K2, PCK1 | MAPT 3880/4885KMT2A 3912/4885MEN1 2885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.